Aerosolized prostacyclin in acute respiratory distress syndrome caused by Chlamydiaceae spp. pneumonia.
Management of respiratory failure in acute respiratory distress syndrome (ARDS) typically requires ventilatory assistance. If traditional approaches to mechanical ventilation and adjunctive measures fail to succeed in achieving adequate oxygenation, alternative measures should be considered. We describe an ARDS patient with respiratory failure caused by a severe Chlamydiaceae species community-acquired pneumonia (CAP). Aerosolized prostacyclin (PGI(2)) treatment was successfully instituted for refractory hypoxemia.
Miesen
W M
WM
Department of Internal Medicine, Division of Intensive Care, Albert Schweitzer Hospital, Location Amstelwijck, P.O. Box 444, 3300 AK Dordrecht, The Netherlands.
Ponssen
H H
HH
Jansen
S
S
Posthuma
R M
RM
van Vliet
A C
AC
D000280:Administration, Inhalation; D002694:Chlamydiaceae Infections / Q000188:drug therapy*; D011464:Epoprostenol / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000382:microbiology
D010975:Platelet Aggregation Inhibitors; D011464:Epoprostenol